Showing 48 out of 59 results
Brexit “no deal” technical notices published on intellectual property and life sciences sector issues
The latest tranche of “no deal” technical notices was released yesterday afternoon by the UK Government. Amongst them are several notices that highlight …
Brexit White Paper highlights importance of Intellectual Property rights post-Brexit
Significantly, for those with interests in IP rights, the UK Government's White Paper on Brexit makes encouraging noises about future recognition and …
Patent and Pharma Update, July 2018
Key recent developments in the United Kingdom and Europe relating to patents and the pharmaceutical sector English courts begin to consider the new …
Comments on UK proposal for the future relationship with the EU
Last Friday, 6 July, it was understood that the UK Cabinet had finally united around a UK position on the desired future relationship with the EU. …
ADVOCATE GENERAL PROVIDES OPINION ON THE INTERPRETATION OF ARTICLE 3(a) SPC REGULATION
Advocate General Wathelet (the "AG") has provided his opinion to the Court of Justice of the European Union (the "CJEU") on the interpretation of Article …
Data use: Protecting a critical resource
The key trends and considerations in safely managing the 'new oil' of the digital economyDescribed by some as the “new oil” for the digital economy, …
Arbitrating Pharma Disputes On The Rise – Planning Ahead Makes Sense
Pharmaceutical companies risk coming up against complex and high value disputes in their everyday dealings and operations, and we are increasingly seeing …
The UK's access to the EU's preferential trade arrangements
The position of the UK under the EU's preferential trade agreements following Brexit is likely to become a major complicating factor in the negotiations. …
Brexit 'The view from Brussels' – developments in January
January was dominated by the strikingly public discussion of the content of the next supplement to the negotiating guidelines that the European Council …
Patent and Pharma update - November 2017
Key recent developments in the United Kingdom and Europe relating to the patents and pharmaceutical sector. One of the most significant developments in …
The view from Brussels – Brexit negotiations – Developments in October
The Brexit debate often looks different viewed from Brussels rather than from London. It is however important for businesses to also keep in mind the …
The High Court considers the doctrine of equivalents in the context of patent infringement and novelty
The High Court in Generics (U.K.) v Yeda Research has considered the correct approach to the interpretation of patent claims in light of the recent …
Showing 48 out of 59 results
View more